Effects of SRT2104 on Exercise Tolerance and Mucsle Metabolism

• Research type

  Research Study

• Full title

  A Phase I, Randomized, Placebo-Controlled, Crossover Study to Assess the Effect of SRT2104 on Exercise Tolerance and Muscle Metabolism in Subjects with Type 2 Diabetes

• IRAS ID

  18575

• Eudract number

  2009-011359-30

• ISRCTN Number

  Not applicable

• Research summary

  Diabetes is a chronic metabolic disorder of which type II is the most prevalent. Type II is an epidemic throughout the world. The Word Health Organisation (WHO) projects by 2030, over 360 million people worldwide will have Type II diabetes. Current therapies do not adequately address insulin resistance associated with Type II diabetes and a significant unmet medical need exists for a novel mechanism of action therapies to treat metabolic diseases such as Type II diabetes. SRT2104 is thought to work by affecting specific proteins which has an overall effect on glucose metabolism. SRT2104 has also been shown to lower blood glucose and increase exercise tolerance. This study will examine the effect of the SRT2104 on its own and in combination with exercise training on the metabolic response to exercise and postprandial (after eating) metabolism and exercise tolerance in subjects with Type II diabetes.

• REC name

  North East - Tyne & Wear South Research Ethics Committee

• REC reference

  09/H0904/31

• Date of REC Opinion

  13 Oct 2009

• REC opinion

  Further Information Favourable Opinion